IL0011319527 - Common Stock
ENLIVEX THERAPEUTICS LTD
NASDAQ:ENLV (4/18/2024, 7:00:02 PM)
After market: 1.39 -0.01 (-0.71%)1.4
-0.08 (-5.41%)
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
ENLIVEX THERAPEUTICS LTD
14 Einstein St.
Ness Ziona 7403618
P: 97286623301
CEO: Oren Hershkovitz
Employees: 77
Website: https://www.enlivex.com/
Let's have a look at the stocks with an unusual volume in today's session.
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. As previously announced, the Company received its first regulatory approval for this trial from the Israeli Ministry of Health (IMOH) in January.
Which stocks are moving on Monday?
Friday's session: top gainers and losers
Here you can normally see the latest stock twits on ENLV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: